Flexi-Myo Panel Strategy: Genomic Diagnoses of Myopathies and Muscular Dystrophies by Next-Generation Sequencing.
Muscle disorders are clinically and genetically heterogeneous. Investigations, including plasma creatine kinase, electromyography, and nerve conduction velocity studies, might be nonspecific, whereas muscle biopsy might be limited by sampling bias and variable histopathology. Next-generation sequencing is now generally considered an important diagnostic tool for muscle disorders, with decreased costs and improved diagnostic yield. Inclusion of a large number of genes in the analysis might, however, generate a large number of ambiguous results and create unnecessary confusion in clinicians and patients. An ethnic Chinese patient presented at age 10 with tip-toe walking, and upon examination revealed a waddling gait, a tight Achilles tendon with pes cavus. A muscle biopsy showed the presence of minicores with disruption of the myofibrillary network and Z-bands. Sequencing was performed using the Flexi-Myo panel that includes coverage of 85 myopathic genes. Sequencing results to be reported were determined by the responsible chemical pathologists taking into account all available clinical information. A heterozygous known in-frame deletion was detected in MYH7, which confirmed the diagnosis of Laing myopathy. No variants of uncertain significance required reporting. We describe the effectiveness of our Flexi-Myo panel approach for the diagnosis of muscle disorders wherein we molecularly characterized a case of Laing myopathy that had a clinically ambiguous presentation. This panel-based approach enables efficient genomic testing for muscle diseases in adults and children with satisfactory diagnostic yield and sufficient sensitivity, whereas avoiding the reporting of ambiguous results. Similar strategies might also be implemented to other group of disorders.